Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter  randomized  double-blind  parallel-group  add-on  superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Brief description of study

This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these two drugs together in comparison to Tecfidera® alone (plus placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    ['Breast Cancer', 'Hereditary Breast/Ovarian Cancer (brca1, brca2)', 'Heart Diseases', 'Drug-Induced Cardiomyopathy']
  • Age: - 99 Years
  • Gender: All


Updated on 14 Aug 2023. Study ID: 828873

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center